期刊文献+

提高对神经-内分泌-免疫网络与创伤脓毒症的认识 被引量:26

原文传递
导出
摘要 尽管当今生物技术及医疗监护手段飞速发展,但创伤后脓毒症(sepsis)的临床治疗收效甚微,其死亡率仍居高不下,系严重创伤最主要的致死性并发症之一。据统计,约40%的脓毒症患者最终会发生休克,每年约有36万欧美患者死于严重脓毒症和多器官损害。重症监护病房约60%的死亡由脓毒性休克所致,这一比例在65岁以上患者群中更高。分析表明,全世界10%的死亡患者与脓毒症密切相关。这些令人震惊的数字提醒我们,脓毒症的防治非常困难,其发病过程牵涉到全身机体的各个系统改变,要提高创伤后脓毒症的临床救治效果必须阐明其确切的病理生理机制,真正做到有的放矢。
出处 《中华创伤杂志》 CAS CSCD 北大核心 2006年第8期561-564,共4页 Chinese Journal of Trauma
  • 相关文献

参考文献16

  • 1Friedman G, Silva E, Vincent JL. Has the mortality of septic shock changed with time. Crit Care Med, 1998, 26:2078 -2086.
  • 2姚咏明,盛志勇.我国创伤脓毒症基础研究新进展[J].中华创伤杂志,2003,19(1):9-12. 被引量:133
  • 3Molina PE. Neurobiology of the stress response: contribution of the sympathetic nervous system to the neuroimmune axis in traumatic injury. Shock, 2005, 24:3-10.
  • 4Oberbeck R. Therapeutic implications of immune - endocrine interactions in the critically ill patients. Curt Drug Targets Immune Endocr Metabol Disord, 2004, 4:129 - 139.
  • 5姚咏明,刘辉,盛志勇.循证医学在脓毒症临床试验中的应用[J].解放军医学杂志,2005,30(7):558-560. 被引量:6
  • 6Andersson J. The inflammatory reflex : introduction. Nature, 2002,420:853 - 859.
  • 7van Westerloo DJ, Giebelen IA, Florquin S, et al. The cholinergic anti - inflammatory pathway regulates the host response during septic peritonitis. J Infect Dis, 2005, 191:2138 -2148.
  • 8Chadda K, Annane D. The use of corticosteroids in severe sepsis and acute respiratory distress syndrome. Ann Med, 2002, 34:582 - 589.
  • 9Law WR, Valli VE, Conlon BA, et al. Therapeutic potential for transient inhibition of adenosine deaminase in systemic inflammatory response syndrome. Crit Care Med, 2003, 31:1475 -1481.
  • 10Vincent JL. Endocrine support in the critically ill. Crit Care Med,2002, 30:702- 703.

二级参考文献25

  • 1阚文宏,闫文生,姜勇,黄巧冰,王静珍,赵克森,王士雯.p38 MAPK在内毒素休克小鼠肺组织诱导型一氧化氮合酶表达中的作用[J].中华老年多器官疾病杂志,2002,1(1):41-47. 被引量:13
  • 2盛志勇.严重创、烧伤后脓毒症与多器官功能障碍综合征的防治[J].中华创伤杂志,2005,21(1):11-14. 被引量:29
  • 3王吉耀. 循证医学的概念. 见:王吉耀主编. 循证医学与临床实践. 北京: 科学出版社, 2002.1
  • 4Bochud PY, Calandra T. Pathogenesis of sepsis: new concepts and implication for future treatment. Br Med J, 2003, 326(7383):262
  • 5Cohen J, Guyatt G, Bernard GR et al. New strategies for clinical trials in patients with sepsis and septic shock. Crit Care Med, 2001, 29(4):880
  • 6Cohen J. Adjunctive therapy in sepsis: a critical analysis of the clinical trial programme. Br Med Bull, 1999, 55(1):212
  • 7Bernard GR, Vincent JL, Laterre PF et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med, 2001, 344(10):699
  • 8Van den Berghe G, Wouters P, Weekers F et al. Intensive insulin therapy in the critically ill patients. N Engl J Med, 2001, 345(19):1359
  • 9Keh D, Sprung CL. Use of corticosteroid therapy in patients with sepsis and septic shock: an evidence-based review. Crit Care Med, 2004, 32(11): S527
  • 10Fang WH;Yao YM;Shi ZG.Effect of recombinant bactericidal/ permeability-increasing protein on endotoxin translocation and lipopolysaccharide-binding protein/CD14 expression in rats after thermal injury,2001.

共引文献137

同被引文献296

引证文献26

二级引证文献209

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部